Abstract
Photodynamic therapy (PDT) was discovered over 100 years ago when it was observed that certain dyes could kill microorganisms when exposed to light in the presence of oxygen. Since those early days, PDT has mainly been developed as a cancer therapy with regulatory approvals and clinical trials steadily accumulating for different types of cancer and different photosensitizer structures. A very important milestone for PDT was the introduction of 5-aminolevulinic acid (ALA), which functions as a prodrug to induce endogenous porphyrin biosynthesis that acts as an endogenous photosensitizer produced by our cells. PDT with ALA and its derivatives have become mainstays of the clinical dermatologist’s practice covering everything from skin cancer, premalignant lesions, acne, and skin rejuvenation. Another milestone in PDT development was the realization that PDT may also be used as an effective antimicrobial modality and a potential treatment for localized infections. To some extent, this means that PDT has gone full circle and returned to its roots from when it was first discovered in 1900. In this chapter we discuss, in a contextualized fashion, what are the expected characteristics of an ideal photosensitizer and which are the main molecular frameworks used for development of synthetic, natural, and nanostructured photosensitizers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin. 2011;61(4):250–81.
Krammer B, Plaetzer K. ALA and its clinical impact, from bench to bedside. Photochem Photobiol Sci. 2008;7(3):283–9.
Verteporfin Roundtable P. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina. 2005;25(2):119–34.
Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci. 2004;3(5):436–50.
Santin GC, Oliveira DS, Galo R, Borsatto MC, Corona SA. Antimicrobial photodynamic therapy and dental plaque: a systematic review of the literature. ScientificWorldJournal. 2014;2014:824538.
Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6(7):535–45.
Huang YY, Tanaka M, Vecchio D, Garcia-Diaz M, Chang J, Morimoto Y, et al. Photodynamic therapy induces an immune response against a bacterial pathogen. Expert Rev Clin Immunol. 2012;8(5):479–94.
Merchat M, Bertolini G, Giacomini P, Villanueva A, Jori G. Meso-substituted cationic porphyrins as efficient photosensitizers of gram-positive and gram-negative bacteria. J Photochem Photobiol B. 1996;32(3):153–7.
Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90(12):889–905.
Kostovic K, Pastar Z, Ceovic R, Mokos ZB, Buzina DS, Stanimirovic A. Photodynamic therapy in dermatology: current treatments and implications. Coll Antropol. 2012;36(4):1477–81.
Wang H, Wang X, Zhang S, Wang P, Zhang K, Liu Q. Sinoporphyrin sodium, a novel sensitizer, triggers mitochondrial-dependent apoptosis in ECA-109 cells via production of reactive oxygen species. Int J Nanomedicine. 2014;9:3077–90.
Kessel D. Photosensitization with derivatives of haematoporphyrin. Int J Radiat Biol Relat Stud Phys Chem Med. 1986;49(6):901–7.
Senge MO, Brandt JC. Temoporfin (Foscan(R), 5,10,15,20-tetra(m-hydroxyphenyl)chlorin) – a second-generation photosensitizer. Photochem Photobiol. 2011;87(6):1240–96.
Chan WM, Lim TH, Pece A, Silva R, Yoshimura N. Verteporfin PDT for non-standard indications – a review of current literature. Graefes Arch Clin Exp Ophthalmol. 2010;248(5):613–26.
Moore CM, Azzouzi AR, Barret E, Villers A, Muir GH, Barber NJ, et al. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. BJU Int. 2015;116(6):888–96.
Anderson CY, Freye K, Tubesing KA, Li YS, Kenney ME, Mukhtar H, et al. A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumors in C3H mice. Photochem Photobiol. 1998;67(3):332–6.
Wainwright M, Crossley KB. Methylene blue – a therapeutic dye for all seasons? J Chemother. 2002;14(5):431–43.
Cincotta L, Foley JW, MacEachern T, Lampros E, Cincotta AH. Novel photodynamic effects of a benzophenothiazine on two different murine sarcomas. Cancer Res. 1994;54(5):1249–58.
Ali MF. Topical delivery and photodynamic evaluation of a multivesicular liposomal Rose Bengal. Lasers Med Sci. 2011;26(2):267–75.
Kawamoto KS,N, Shimada K, Ito K, Hirano Y, Murai S. Antibacterial effect of yellow He-Ne laser irradiation with crystal violet solution on porphyromonas gingivalis: an evaluation using experimental rat model involving subcutaneous abscess. Lasers Med Sci. 2000;15(4):5.
Prates RA, Yamada Jr AM, Suzuki LC, Eiko Hashimoto MC, Cai S, Gouw-Soares S, et al. Bactericidal effect of malachite green and red laser on Actinobacillus actinomycetemcomitans. J Photochem Photobiol B Biol. 2007;86(1):70–6.
Shafeekh KM, Soumya MS, Rahim MA, Abraham A, Das S. Synthesis and characterization of near-infrared absorbing water soluble squaraines and study of their photodynamic effects in DLA live cells. Photochem Photobiol. 2014;90(3):585–95.
Rice DR, Gan H, Smith BD. Bacterial imaging and photodynamic inactivation using zinc(ii)-dipicolylamine BODIPY conjugates. Photochem Photobiol Sci. 2015;14(7):1271–81.
Cieplik F, Spath A, Regensburger J, Gollmer A, Tabenski L, Hiller KA, et al. Photodynamic biofilm inactivation by SAPYR – an exclusive singlet oxygen photosensitizer. Free Radic Biol Med. 2013;65:477–87.
Theodossiou TA, Hothersall JS, De Witte PA, Pantos A, Agostinis P. The multifaceted photocytotoxic profile of hypericin. Mol Pharm. 2009;6(6):1775–89.
Maisch T, Eichner A, Spath A, Gollmer A, Konig B, Regensburger J, et al. Fast and effective photodynamic inactivation of multiresistant bacteria by cationic riboflavin derivatives. PLoS ONE. 2014;9(12):e111792.
Tortik N, Steinbacher P, Maisch T, Spaeth A, Plaetzer K. A comparative study on the antibacterial photodynamic efficiency of a curcumin derivative and a formulation on a porcine skin model. Photochem Photobiol Sci. 2016;15(2):187–95.
Lei W, Zhou Q, Jiang G, Zhang B, Wang X. Photodynamic inactivation of Escherichia coli by Ru(II) complexes. Photochem Photobiol Sci Off J Eur Photochem Assoc Eur Soc Photobiol. 2011;10(6):887–90.
El-Hussein A, Mfouo-Tynga I, Abdel-Harith M, Abrahamse H. Comparative study between the photodynamic ability of gold and silver nanoparticles in mediating cell death in breast and lung cancer cell lines. J Photochem Photobiol B. 2015;153:67–75.
Chu CK, Tu YC, Hsiao JH, Yu JH, Yu CK, Chen SY, et al. Combination of photothermal and photodynamic inactivation of cancer cells through surface plasmon resonance of a gold nanoring. Nanotechnology. 2016;27(11):115102.
Meziani MJ, Dong X, Zhu L, Jones LP, LeCroy GE, Yang F, et al. Visible-light-activated bactericidal functions of carbon “Quantum” dots. ACS Appl Mater Interfaces. 2016;8(17):10761–6.
Li S, Chang K, Sun K, Tang Y, Cui N, Wang Y, et al. Amplified singlet oxygen generation in semiconductor polymer dots for photodynamic cancer therapy. ACS Appl Mater Interfaces. 2016;8(6):3624–34.
Jin S, Zhou L, Gu Z, Tian G, Yan L, Ren W, et al. A new near infrared photosensitizing nanoplatform containing blue-emitting up-conversion nanoparticles and hypocrellin A for photodynamic therapy of cancer cells. Nanoscale. 2013;5(23):11910–8.
Spyropoulos-Antonakakis N, Sarantopoulou E, Trohopoulos PN, Stefi AL, Kollia Z, Gavriil VE, et al. Selective aggregation of PAMAM dendrimer nanocarriers and PAMAM/ZnPc nanodrugs on human atheromatous carotid tissues: a photodynamic therapy for atherosclerosis. Nanoscale Res Lett. 2015;10:210.
Bastien E, Schneider R, Hackbarth S, Dumas D, Jasniewski J, Roder B, et al. PAMAM G4.5-chlorin e6 dendrimeric nanoparticles for enhanced photodynamic effects. Photochem Photobiol Sci. 2015;14(12):2203–12.
Senge MO. mTHPC – a drug on its way from second to third generation photosensitizer? Photodiagnosis Photodyn Ther. 2012;9(2):170–9.
Tu J, Wang T, Shi W, Wu G, Tian X, Wang Y, et al. Multifunctional ZnPc-loaded mesoporous silica nanoparticles for enhancement of photodynamic therapy efficacy by endolysosomal escape. Biomaterials. 2012;33(31):7903–14.
Hamblin MR, Newman EL. On the mechanism of the tumour-localising effect in photodynamic therapy. J Photochem Photobiol B. 1994;23(1):3–8.
Goff BA, Hermanto U, Rumbaugh J, Blake J, Bamberg M, Hasan T. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br J Cancer. 1994;70(3):474–80.
Kascakova S, Hofland LJ, De Bruijn HS, Ye Y, Achilefu S, van der Wansem K, et al. Somatostatin analogues for receptor targeted photodynamic therapy. PLoS ONE. 2014;9(8):e104448.
Demidova TN, Hamblin MR. Effect of cell-photosensitizer binding and cell density on microbial photoinactivation. Antimicrob Agents Chemother. 2005;49(6):2329–35.
Demidova TN, Hamblin MR. Macrophage-targeted photodynamic therapy. Int J Immunopathol Pharmacol. 2004;17(2):117–26.
You H, Yoon HE, Jeong PH, Ko H, Yoon JH, Kim YC. Pheophorbide-a conjugates with cancer-targeting moieties for targeted photodynamic cancer therapy. Bioorg Med Chem. 2015;23(7):1453–62.
El-Akra N, Noirot A, Faye JC, Souchard JP. Synthesis of estradiol-pheophorbide a conjugates: evidence of nuclear targeting, DNA damage and improved photodynamic activity in human breast cancer and vascular endothelial cells. Photochem Photobiol Sci. 2006;5(11):996–9.
Ballut S, Makky A, Chauvin B, Michel JP, Kasselouri A, Maillard P, et al. Tumor targeting in photodynamic therapy. From glycoconjugated photosensitizers to glycodendrimeric one. Concept, design and properties. Org Biomol Chem. 2012;10(23):4485–95.
Zou Q, Zhao H, Zhao Y, Fang Y, Chen D, Ren J, et al. Effective two-photon excited photodynamic therapy of xenograft tumors sensitized by water-soluble bis(arylidene)cycloalkanone photosensitizers. J Med Chem. 2015;58(20):7949–58.
Zhang X, Ai F, Sun T, Wang F, Zhu G. Multimodal upconversion nanoplatform with a mitochondria-targeted property for improved photodynamic therapy of cancer cells. Inorg Chem. 2016;55(8):3872–80.
Kachynski AV, Pliss A, Kuzmin AN, Ohulchanskyy XTY, Baev A, Qu J, et al. Photodynamic therapy by in situ nonlinear photon conversion. Nat Photonics. 2014;8:455–61.
Gryson O. Servier medical art France: servier. 2016. Available from: http://www.servier.com/Powerpoint-image-bank.
Acknowledgments
MR Hamblin was supported by US NIH grant R01AI050875.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Hamblin, M.R., Sabino, C.P. (2016). Photosensitizers. In: Sellera, F., Nascimento, C., Ribeiro, M. (eds) Photodynamic Therapy in Veterinary Medicine: From Basics to Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-45007-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-45007-0_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-45006-3
Online ISBN: 978-3-319-45007-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)